Preoperative suspicion of malignancy in nonfunctioning pancreatic neuroendocrine tumors (pNETs) is mostly based on tumor size. We retrospectively analyzed the contrast enhanced ultrasound (CEUS) features of a series of histopathologically proved nonfunctioning pNETs.
METHODS:
In this retrospective study, 37 surgery and histologically proved nonfunctioning pNETs were included. All pNETs lesions were incidentally detected by transabdominal ultrasound. B mode ultrasound (BMUS) and CEUS features were reviewed and analyzed. 52 histopathologically proved pancreatic ductal adenocarcinoma (PDACs) lesions were included as a control group.
RESULTS:
All nonfunctioning pNETs patients showed no typical clinical symptoms. No significant differences were observed in size, echogenicity or internal color flow imaging signal between pNETs and PDAC patients (P > 0.05). Most of nonfunctioning pNETs showed a well-defined tumor margin. The presence of pancreatic duct dilatation was less frequently observed in nonfunctioning pNETs patients (P < 0.05). After injection of ultrasound contrast agents, homogeneous enhancement was more commonly observed in nonfunctioning pNETs group (P < 0.05). During arterial phase of CEUS, most of nonfunctioning pNETs were hyper- or isoenhanced (32/37, 86.5%), whereas most of PDACs were hypoenhanced (34/52, 65.4%) (P < 0.05). Nonenhanced necrosis area was more commonly detected in PDACs (P = 0.012).
CONCLUSIONS:
CEUS features are helpful for preoperative non-invasive differential diagnosis of nonfunctioning pNETs, assisting further clinical decision-making process.
YamamotoY, et al. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor. Ann Surg Oncol. 2017;24(8):2363–70.
5.
DromainC, et al. Imaging of neuroendocrine tumors of the pancreas. Diagn Interv Imaging. 2016;97(12):1241–57.
6.
CloydJM, PoultsidesGA, Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol. 2015;21(32):9512–25.
7.
DietrichCF, et al. Differential diagnosis of small solid pancreatic lesions. Gastrointest Endosc. 2016;84(6):933–40.
8.
DietrichCF, et al. Improved differentiation of pancreatic tumors using contrast-enhanced endoscopic ultrasound. Clin Gastroenterol Hepatol. 2008;6(5):590–7e1.
9.
WernerJM, et al. Intraoperative contrast-enhanced ultrasound can have a crucial role in surgical decision-making during hepato-pancreatico-biliary surgery - Analysis of impact and input. Clin Hemorheol Microcirc. 2021;78(1):103–16.
10.
XieJ, et al. Quantitative shear wave elastography for noninvasive assessment of solid pancreatic masses. Clin Hemorheol Microcirc. 2020;74(2):179–87.
11.
WildnerD, et al. Differentiation of malignant liver tumors by software-based perfusion quantification with dynamic contrast-enhanced ultrasound (DCEUS). Clin Hemorheol Microcirc. 2019;71(1):39–51.
12.
LossM, et al. Intraoperative high resolution linear contrast enhanced ultrasound (IOUS) for detection of microvascularization of malignant liver lesions before surgery or radiofrequeny ablation. Clin Hemorheol Microcirc. 2012;50(1-2):65–77.
13.
D’OnofrioM, et al. CEUS of the pancreas: Still research or the standard of care. Eur J Radiol. 2015;84(9):1644–9.
14.
WangY, et al. Contrast-Enhanced Ultrasonography of Pancreatic Carcinoma: Correlation with Pathologic Findings. Ultrasound Med Biol. 2016;42(4):891–8.
15.
D’OnofrioM, et al. Diagnostic performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced endoscopic ultrasound (ECEUS) for the differentiation of pancreatic lesions: a systematic review and meta-analysis. Ultraschall Med. 2014;35(6):515–21.
16.
KitanoM, et al. Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography. Am J Gastroenterol. 2012;107(2):303–10.
17.
SidhuPS, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update (Short Version). Ultraschall Med. 2018;39(2):154–80.
18.
SidhuPS, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update (Long Version). Ultraschall Med. 2018;39(2):e2–e44.
19.
TemperoMA, et al. Pancreatic Adenocarcinoma, Version 2. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028–61.
20.
PartelliS, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017;105(3):255–65.
21.
CivesM, StrosbergJR, Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018;68(6):471–87.
22.
LombardiM, et al. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET. J Endocrinol Invest. 2015;38(6):605–13.
23.
WatzkaFM, et al. Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies. World J Surg. 2020;44(2):594–603.
24.
BettiniR, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19(5):903–8.
25.
AllenPJ, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Ann Surg. 2017;265(1):185–91.
26.
PuleoF, et al. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology. 2018;155(6):1999–2013e3.
27.
PuliSR, et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis. World J Gastroenterol. 2013;19(23):3678–84.
28.
KhashabMA, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointestinal Endoscopy. 2011;73(4):691–6.
29.
FigueiredoFA, et al. EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc. 2009;70(5):907–14.
30.
MiuraF, et al. Diagnosis of pancreatic cancer. HPB (Oxford). 2006;8(5):337–42.
31.
SofuniA, Tsuchiya T, Itoi T. Ultrasound diagnosis of pancreatic solid tumors. J Med Ultrason. 2020;47(3):359–76.
32.
D’OnofrioM, et al. Neuroendocrine pancreatic tumor: value of contrast enhanced ultrasonography. Abdom Imaging. 2004;29(2):246–58.
33.
KulkeMH, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13(1):78–108.
34.
GallottiA, et al. Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy. AJR Am J Roentgenol. 2013;200(2):355–62.
35.
SharmaC, et al. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: –World J Gastroenterol2011;17(7):867–97.
36.
LiXZ, et al. Diagnostic performance of contrast-enhanced ultrasound for pancreatic neoplasms: A systematic review and meta-analysis. Dig Liver Dis. 2018;50(2):132–8.
37.
DietrichCF, et al. Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound (vol 134, pg 6, 2008). Journal of Cancer Research and Clinical Oncology2008;134(6):723–723.
38.
MalagoR, et al. Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2009;192(2):424–30.
39.
FalconiM, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95(2):120–34.
40.
RodallecM, et al. Endocrine pancreatic tumours and helical CT: Contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology. 2006;6(1-2):77–85.
41.
HataH, et al. Fibrous stroma and vascularity of pancreatic carcinoma: correlation with enhancement patterns on CT. Abdom Imaging. 2010;35(2):172–80.
42.
TakadaS, et al. Contrast-enhanced harmonic endoscopic ultrasound using time-intensity curve analysis predicts pathological grade of pancreatic neuroendocrine neoplasm. J Med Ultrason. 2019;46(4):449–58.
